Several analysts have recently updated their ratings and price targets for Pacira Pharmaceuticals (NASDAQ: PCRX):

  • 9/7/2017 – Pacira Pharmaceuticals is now covered by analysts at Oppenheimer Holdings, Inc.. They set a “market perform” rating on the stock.
  • 9/7/2017 – Pacira Pharmaceuticals is now covered by analysts at CIBC. They set a “market perform” rating on the stock.
  • 9/7/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $59.00 price target on the stock.
  • 9/6/2017 – Pacira Pharmaceuticals is now covered by analysts at UBS AG. They set a “market perform” rating on the stock.
  • 9/5/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $54.00 price target on the stock.
  • 8/29/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at Canaccord Genuity from $56.00 to $48.00. They now have a “buy” rating on the stock.
  • 8/23/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 8/22/2017 – Pacira Pharmaceuticals is now covered by analysts at Needham & Company LLC. They set a “buy” rating and a $55.00 price target on the stock.
  • 8/22/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $53.00 price target on the stock, down previously from $54.00.
  • 8/21/2017 – Pacira Pharmaceuticals was upgraded by analysts at Janney Montgomery Scott from a “sell” rating to a “neutral” rating. They now have a $31.00 price target on the stock.
  • 8/11/2017 – Pacira Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Pacira incurred wider-than-expected loss in second-quarter 2017 and revenues missed estimates. the company efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company also remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Going forwad, Pacira is looking to expand Exparel's label in the animal health market as well. Shares of the company have outperformed the industry year to date. However, Pacira’s dependence on its key marketed drug, Exparel, for top-line growth is concerning. A decline in Exparel sales will adversely impact the company's top line.The company also discontinued the production of DepoCyt(e) due to persistent technical issues specific to DepoCyt.”
  • 8/4/2017 – Pacira Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/3/2017 – Pacira Pharmaceuticals was given a new $59.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/3/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $42.00 to $40.00. They now have a “market perform” rating on the stock.
  • 8/2/2017 – Pacira Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company.
  • 8/2/2017 – Pacira Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/31/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $56.00 price target on the stock.
  • 7/30/2017 – Pacira Pharmaceuticals was given a new $58.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 7/27/2017 – Pacira Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/26/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $54.00 price target on the stock.
  • 7/25/2017 – Pacira Pharmaceuticals was given a new $56.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/19/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.

Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) traded down 2.11% during midday trading on Friday, hitting $37.05. 712,550 shares of the stock were exchanged. The company’s 50 day moving average is $37.19 and its 200 day moving average is $44.54. The company’s market capitalization is $1.49 billion. Pacira Pharmaceuticals, Inc. has a 1-year low of $29.95 and a 1-year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). The company had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the company posted $0.21 earnings per share. Analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the completion of the sale, the chief accounting officer now owns 21,312 shares of the company’s stock, valued at $783,216. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the completion of the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $5,788,794.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,390 shares of company stock valued at $1,215,480. 6.60% of the stock is owned by insiders.

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.